Sana Biotechnology

Sana shares 14-month data for ‘functional cure’ diabetes program

Sana is evaluating a donor-derived primary islet cell therapy designed to serve as a Type 1 diabetes treatment that doesn’t require immunosuppression.

Gabrielle Masson Mar 13, 2026 10:55am

reshuffle pipeline target reorganize shift change

Sana, CAMP4 ditch clinical-stage assets for preclinical hopefuls

Nov 7, 2025 8:13am

Sana stock price triples after allogeneic cell therapy data drop

Jan 8, 2025 10:38am

team funding workforce workforce reductions cash runway

Sana strips back cancer, CNS programs while warning of layoffs

Nov 5, 2024 7:05am

Paragliding with Mount Rainier in the background

Cell-focused Sana scoops first CSO—Chutes & Ladders

Aug 30, 2024 8:30am

Small white blocks with black text that say Diabetes Type 1 in all caps surrounded by syringes containing a blue liquid th

Sana's engineered islet cells control glucose in diabetic monkey

Feb 15, 2024 2:55pm